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Pain from arthritis is a common symptom for which patients often seek medical attention. In fact, osteoarthritis (OA) is the most common joint disorder in the USA and affects 10% of men and 13% ofwomen aged 60 years or older, 1 and the prevalence rates are comparable in Europe. 2 Current strategies for managing arthritis pain include analgesics such as acetominophen and aspirin, narcotic analgesics (opioids), traditional non-steroidal anti-inflammatory drugs (NSAIDs), and selective cyclooxygenase 2 inhibitors (coxibs). The global pain market in 2009 was valued at >US$50 billion, including US$27 billion in the seven major economies with 35% of the sales from NSAIDs and coxibs. 3 Thus these drugs have wide use in the general population, with important implications for understanding their safety, efficacy, and cost-effectiveness. In this issue of the journal, MacDonald et al. 4 report on the cardiovascular safety of switching to celecoxib vs. continuing NSAID therapy in a European setting. The investigators used a prospective randomized open blinded endpoint (PROBE) study design where individuals aged 60 years and over with OA or rheumatoid arthritis, free from established cardiovascular (CV) disease, and taking chronic prescribed NSAIDs, were randomized to switch to celecoxib or to continue their previous NSAID. In this study, CV events were infrequent and similar on celecoxib and NSAIDs, with no advantage of a strategy of switching prescribed NSAIDs to prescribed celecoxib. Despite some power limitations due to enrolment of fewer patients than expected, this study provides important insight into the relative safety and benefit of NSAIDs and celecoxib. First of all, it appears that NSAID or celecoxib therapy is safe, with low observed CV event rates noted in older subjects with typical CV risk factors but without established CV disease. Secondly, the dominant reason recorded for the higher withdrawal in those allocated to switch to celecoxib was lack of efficacy, suggesting that there are important clinical differences in efficacy of NSAIDs, with some indirect evidence that diclofenac may be more effective than ibuprofen and celecoxib. Thirdly, the increasing co-prescription of antiulcer drugs appears to have ameliorated NSAID-associated gastrointestinal complications, further reducing the rationale for switching patients established on NSAIDs to celecoxib. Overall, there appears to be minimal rationale to switch from NSAIDs to celecoxib in the primary care setting. Given these and other available data, clinicians should consider efficacy, safety, drug interactions, and cost in choosing NSAIDs for an individual patient (Figure 1) . Some overarching principles include avoiding coxibs (and possibly diclofenac) in individuals with known coronary artery disease, history of a stroke, and vascular disease based on safety concerns. [5] [6] [7] In addition, antiulcer drugs are indicated for most patients with traditional NSAIDs and in particular for those with a history of a symptomatic or complicated upper gastrointestinal ulcer. 8 For those patients who have had an upper gastrointestinal bleed within the past year, clinicians may consider using a coxib in combination with a proton pump inhibitor. In general, clinicians should use the most effective drug for that patient for the shortest duration and lowest dose possible. The Coxib and traditional NSAID Trialists' (CNT) Collaboration reported that the CV risks of high-dose diclofenac and ibuprofen were comparable with those of coxibs, whereas naproxen at 500 mg twice a day was associated with less CV risk than other NSAIDs. 9 Although NSAIDs and coxibs increase vascular and gastrointestinal risks, the size of these risks may help guide clinical decision-making for an individual patient. The ongoing Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION) trial 10 will provide additional insight on the relative safety of NSAIDs and coxibs.
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